Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 9/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 3/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5444561 | 0.81 | BCHE (0.46) | BCHEMEN1KMT2A | |
| SCHEMBL3563691 | 0.77 | METAP2 (0.47) | MEN1KMT2APOLBNPC1 | |
| SCHEMBL6825701 | 0.77 | DNM1 (0.38) | MEN1KMT2ANPC1BACE1CTSD | |
| SCHEMBL5437755 | 0.76 | BCHE (0.48) | BCHEBACE1 | |
| SCHEMBL18076397 | 0.75 | DNM1 (0.56) | BCHEBACE1 | |
| SCHEMBL5433895 | 0.75 | PLA2G1B (0.57) | BCHEMEN1KMT2APOLB | |
| SCHEMBL18076414 | 0.72 | KMT2A (0.55) | BCHEMEN1KMT2ANPC1 | |
| SCHEMBL17057052 | 0.71 | ADRB2 (0.43) | MEN1KMT2APOLBBACE1CTSD | |
| SCHEMBL29860418 | 0.71 | HTT (0.40) | BCHE | |
| SCHEMBL3122891 | 0.71 | CYP2D6 (0.57) | BCHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | BCHE 8/4885MEN1 2249/4885KMT2A 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.